Terapijske mogućnosti liječenja intersticijskih bolesti pluća u sklopu sistemskih reumatskih bolesti – primjer sistemske skleroze

Professional paper - Professional paper

• Title (english): Therapeutic options for the treatment of interstitial lung diseases in systemic rheumatic diseases – systemic sclerosis as an example
• Author: Marko Barešić; MBZ: 224326
• Author: Branimir Anić
• Author's institution: University of Zagreb; School of Medicine; (Department of Internal Medicine)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine

Abstract (croatian)

Sistemska skleroza je sustavna bolest vezivnog tkiva autoimunosne etiologije karakterizirana stvaranjem fibroze, prvenstveno kože, ali i plućnog parenhima. Intersticijska bolest pluća jedna je od najtežih manifestacija bolesti te ujedno i vodeći uzrok smrti oboljelih od sistemske skleroze. Prikazan je kratak pregled terapijskih mogućnosti liječenja intersticijske bolesti pluća kod bolesnika sa sistemskom sklerozom i srodnim autoimunosnim bolestima. Terapijske mogućnosti prvenstveno uključuju imunosupresive i biološke lijekove (ciklofosfamid, mikofenolat mofetil te rituksimab i tocilizumab), a potom i lijekove koji djeluju na patogenezu remodeliranja fibroznog tkiva (antifibrotici). Sve je više dokaza da bi kombininacija imunosupresivne i antifibrotske terapije mogla imati povoljan učinak na plućnu komponentu bolesti. U zadnje se vrijeme transplantacija autolognih krvotvornih matičnih stanica nudi kao terapijski izbor za skupinu bolesnika s progresivnim tijekom bolesti, no metoda je ograničena na centre koji imaju iskustva s transplantacijom.

Abstract (english)

Systemic sclerosis is a multisystem autoimmune disorder characterized by widespread fibrosis, primarily of the skin but also of the lung parenchyma. Interstitial lung disease is one of the most severe manifestations of the disease and a leading cause of death among patients with systemic sclerosis. This article presents and summarizes therapeutic options for interstitial lung disease – predominantely immunosuppressives and biologics (cyclophosphamide, mycophenolate mofetil, rituximab and tocilizumab) and the drugs which remodel fibrotic tissue (antifibrotics). There is increasing evidence for a beneficial effect of combination therapy (immunosuppressive + antifibrotic) on the lung parenchyma. Recently, autologous hematopoietic stem cell transplantation seems to be a therapeutic method reserved for the treatment of progressive forms of systemic sclerosis and should be
performed in medical centers with experience in transplantation medicine.

• Keywords (croatian): INTERSTICIJSKA BOLEST PLUĆA – etiologija, farmakoterapija; SISTEMSKA SKLEROZA – farmakoterapjja, komplikacije; IMUNOSUPRESIVI – terapijska uporaba; CIKLOFOSFAMID – terapijska uporaba; MIKOFENOLNA KISELINA – terapijska uporaba; RITUKSIMAB – terapijska uporaba; HUMANIZIRANA MONOKLONSKA PROTUTIJELA – terapijska uporaba; INDOLI – terapijska uporaba; PIRIDONI – terapijska uporaba; TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA; AUTOLOGNA TRANSPLANTACIJA
• Keywords (english): LUNG DISEASES, INTERSTITIAL – drug therapy, etiology; SCLERODERMA, SYSTEMIC – complications, drug therapy; IMMNUNOSUPPRESSIVE AGENTS – therapeutic use; CYCLOPHOSPHAMIDE – therapeutic use; MYCOPHENOLIC ACID – therapeutic use; RITUXIMAB – therapeutic use; ANTIBODIES, MONOCLONAL, HUMANIZED – therapeutic use; INDOLES – therapeutic use; PYRIDONES – therapeutic use; HEMATOPOIETIC STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS
• Language: croatian
• Language: english
• Publication type: Professional paper - Professional paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Liječnički vjesnik
• Numbering: vol. 144, no. 3-4, pp. 112-116
• p-ISSN: 0024-3477
• e-ISSN: 1849-2177
• DOI: https://doi.org/10.26800/LV-144-3-4-8
• URN:NBN: urn:nbn:hr:105:121923
• Publication: 2022
• Document URL: https://hrcak.srce.hr/274651
• Type of resource: Text
• Access conditions: Open access
• Created on: 2022-05-23 08:20:03